Shares of Embecta Corp. (NASDAQ:EMBC – Get Free Report) passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $6.13 and traded as low as $5.98. Embecta shares last traded at $6.09, with a volume of 715,677 shares.
Analysts Set New Price Targets
Separately, Weiss Ratings raised shares of Embecta from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, November 2nd. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Embecta has an average rating of “Reduce” and a consensus target price of $11.00.
Check Out Our Latest Research Report on Embecta
Embecta Stock Down 2.9%
The company has a market capitalization of $340.53 million, a P/E ratio of 3.06 and a beta of 0.81. The business has a 50 day moving average of $6.05 and a 200 day moving average of $6.08.
Insider Activity
In other news, Director Milton Mayo Morris sold 6,293 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the sale, the director directly owned 53,828 shares of the company’s stock, valued at $316,508.64. This represents a 10.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by company insiders.
Institutional Investors Weigh In On Embecta
Large investors have recently bought and sold shares of the business. DGS Capital Management LLC raised its stake in Embecta by 5.0% during the third quarter. DGS Capital Management LLC now owns 68,342 shares of the company’s stock valued at $387,000 after purchasing an additional 3,278 shares in the last quarter. Ancora Advisors LLC bought a new position in Embecta during the third quarter valued at $90,000. Allworth Financial LP grew its stake in shares of Embecta by 234.1% in the 3rd quarter. Allworth Financial LP now owns 4,707 shares of the company’s stock worth $27,000 after buying an additional 3,298 shares in the last quarter. Cetera Investment Advisers grew its stake in shares of Embecta by 47.2% in the 3rd quarter. Cetera Investment Advisers now owns 46,075 shares of the company’s stock worth $261,000 after buying an additional 14,768 shares in the last quarter. Finally, Pathstone Holdings LLC grew its stake in shares of Embecta by 2.6% in the 3rd quarter. Pathstone Holdings LLC now owns 71,246 shares of the company’s stock worth $419,000 after buying an additional 1,819 shares in the last quarter. Institutional investors own 93.83% of the company’s stock.
Embecta Company Profile
Embecta is a medical device company focused on products for people who use insulin to manage diabetes. Its portfolio includes pen needles, insulin syringes and safety injection devices, serving both individuals and healthcare professionals. The company was formed in 2022 when Becton, Dickinson and Company (BD) separated its diabetes care business into an independent company. Embecta continues to build on that business’s history of developing injection devices for diabetes care. Embecta serves customers in markets around the world.
Further Reading
- Five stocks we like better than Embecta
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
